Status:
TERMINATED
Evaluation of Impact of Sandostatin® Injection Before Axillary Clearance on Lymphocele Formation
Lead Sponsor:
Institut Cancerologie de l'Ouest
Conditions:
Breast Cancer
Lymphocele
Eligibility:
FEMALE
18+ years
Phase:
NA
Brief Summary
The lymphocele is the main early postoperative complication of axillary clearance for breast cancer patients with rates up to 85%. The usual treatment consists of external drainage. However, this met...
Eligibility Criteria
Inclusion
- Breast cancer, histologically proven Axillary clearance Elective axillary approach Age ≥ 18 years OMS \< 3 Normal hematological and hepatic blood tests Obtaining the signed written consent of the patient
Exclusion
- Axillary clearance with a mastectomy Metastatic disease Disorder precluding understanding of trial information or informed consent Pregnancy, breastfeeding women Patient is willing and able to comply with the protocol for the duration of the study including all scheduled treatment, visits and examinations No severe or uncontrolled diabetes Known hypersensitivity to Octreotide Patient with vitamin B12 deficiency Anticoagulant treatment History of cardiovascular disease Other product being tested in the 4 weeks prior to the start of treatment Patient has valid health insurance
Key Trial Info
Start Date :
July 6 2016
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
July 6 2018
Estimated Enrollment :
4 Patients enrolled
Trial Details
Trial ID
NCT03791736
Start Date
July 6 2016
End Date
July 6 2018
Last Update
July 28 2022
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.